Values First Advisors Inc. Sells 38,497 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Values First Advisors Inc. cut its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 51.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,032 shares of the company’s stock after selling 38,497 shares during the quarter. Values First Advisors Inc.’s holdings in Zentalis Pharmaceuticals were worth $109,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Erste Asset Management GmbH bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $37,000. Paloma Partners Management Co acquired a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $37,000. Aigen Investment Management LP bought a new position in Zentalis Pharmaceuticals in the third quarter worth $41,000. Capstone Investment Advisors LLC acquired a new stake in Zentalis Pharmaceuticals during the third quarter worth $48,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after buying an additional 5,333 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Guggenheim reduced their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Wells Fargo & Company dropped their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. HC Wainwright decreased their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Wedbush reissued a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Finally, UBS Group cut their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.24.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka bought 60,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Ingmar Bruns purchased 20,000 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Trading Up 3.8 %

NASDAQ:ZNTL opened at $2.16 on Thursday. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.61 and a 1 year high of $18.07. The firm has a 50 day moving average of $2.69 and a 200-day moving average of $3.14.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. On average, equities research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.